MarginsXMarginsX
Home › Markets › Health Care › AVTX

Avalo Therapeutics Inc. (AVTX)

AVTX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$7.37
-5.03% on the day
Market cap
$426.2M
Small cap
Revenue · 2025
$59K
-86.6% on 2024
Net income · 2025
-$78.3M
-132642.4% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1534120/000153412026000011/0001534120-26-000011-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerAVTX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2015
SEC CIK0001534120
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$59K
Net income-$78.3M
Operating income-$72.9M
Net margin-132642.4%
Operating margin-123601.7%
Revenue growth-86.6%
Cash$15.9M
Total assets$116.5M
P/E (computed)Net income was not positive
P/S (computed)7223.0×

Warning signs

Cash runway
12.3 months
$65.0M cash at September 30, 2026
Share count, 1 year
+218.9%
2025-11-03 to 2026-11-02 · +7113.5% over 3 years
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
-$8.5M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-05
Cash and burn$65.0M cash; operating cash flow -$15.9M a quarter.Report 2026-09-30
Shares outstanding57,823,083 (2026-11-02); 18,133,968 a year earlier; 192,382,419 three years earlier. 3y figure adjusted for splits (1-for-240 overall).Cover page 2026-11-02
Reverse splits, 3 years1; latest 1-for-240 on 2023-12-29Source 2023-12-29
Shelf and offerings, 12 months3 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the marketLatest 2026-11-05
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Jericho, New York, United StatesPCAOB Form AP 2026-04-07
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $8.5M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$18.9M-$11.5M$65.0MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q2 2026
2026-06-30
Not filed-$36.4M-$20.0M$85.4MNo debt tagsNeeds four quarters10-Q 2026-08-06
Q1 2026
2026-03-31
Not filed-$19.6M-$17.7M$25.0MNo debt tagsNeeds four quarters10-Q 2026-05-13
Q4 2025
2025-12-31
$59K-$13.7M-$14.2M$15.9MNo debt tags$59K10-K 2026-03-23
Q3 2025
2025-09-30
$0-$30.6M-$16.4M$27.0MNo debt tagsNeeds four quarters10-Q 2025-11-06
Q2 2025
2025-06-30
Not filed-$20.8M-$11.4M$42.3MNo debt tagsNeeds four quarters10-Q 2026-08-06
Q1 2025
2025-03-31
Not filed-$13.1M-$9.5M$125.0MNo debt tagsNeeds four quarters10-Q 2026-05-13
Q4 2024
2024-12-31
$192K-$35.3M-$15.0M$134.5MNo debt tags$441K10-K 2026-03-23

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-3ASR2026-11-05
Latest annual report10-K2026-03-23
Latest quarterly / interim10-Q2026-11-05
Latest current report
FORM 8-K
8-K2026-11-05
Latest proxyDEFA14A2026-04-10

Source: SEC EDGAR submissions feed, 1,006 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+12.0%
1 month-35.4%
3 months-60.1%
Year to date-57.3%
1 year-47.3%
From 52-week high-66.1%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
CTMXCytomX Therapeutics Inc.$1.99-2.70%$432.7M
BLSMBlossomHill Therapeutics Inc.$13.65-2.64%$433.9M
ASMBAssembly Biosciences Inc.$21.29+0.80%$436.0M
EOLSEvolus Inc.$6.63-4.74%$438.8M
ARVNArvinas Inc.$6.77-0.73%$443.3M
PRTAProthena Corporation plc$7.97-2.33%$409.3M
MPLTMapLight Therapeutics Inc.$6.90-4.83%$446.9M
DMACDiaMedica Therapeutics Inc.$8.33-5.23%$449.5M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier